Clinical Laboratory Price Transparency Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Clinical Laboratory Price Transparency Act of 2023 is a proposed bill introduced in the House during the 118th Congress. The bill aims to address issues related to price transparency in clinical laboratory testing. Although the full text and official summary are not available, the bill's title and policy area indicate a focus on improving the availability of pricing information for clinical laboratory services. The bill was referred to the Subcommittee on Health but ultimately failed or expired without further legislative action.
This bill sought to enhance price transparency in clinical laboratory testing but did not advance beyond initial committee referral and expired in the 118th Congress.
- The bill is titled the Clinical Laboratory Price Transparency Act of 2023 and relates to the health policy area.
- It was introduced in the House of Representatives during the 118th Congress.
- The latest recorded action was referral to the Subcommittee on Health on December 17, 2024.
- The bill did not progress further and is currently classified as failed or expired.
- No official summary or full text is publicly available to provide detailed provisions.
['Patients seeking clearer pricing information for clinical laboratory tests', 'Healthcare providers and clinical laboratories potentially affected by transparency requirements', 'Health insurers and payers interested in cost management', 'Regulatory bodies overseeing healthcare pricing and transparency']
['Lack of publicly available full text limits understanding of specific implementation mechanisms and enforcement provisions', 'Potential administrative and compliance costs for clinical laboratories to disclose pricing information', 'Oversight and enforcement authority details are not available, raising questions about accountability', 'Unclear how the bill addresses variations in pricing across different laboratories and regions']
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not advance beyond this stage and expired without becoming law. The focus on price transparency aligns with ongoing legislative interest in healthcare cost containment and consumer information, but no further legislative activity was recorded.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Improved price transparency could influence patient decision-making and competition among clinical laboratories if implemented.', 'Potential administrative burden on laboratories to collect and report pricing data.', 'Possible impact on healthcare costs and insurance reimbursement practices depending on transparency outcomes.']
The absence of the bill's full text and official summary limits the ability to fully assess the scope, enforcement, and detailed policy implications of the Clinical Laboratory Price Transparency Act of 2023. Transparency about legislative content is crucial for public understanding and oversight. Monitoring future proposals on this topic should include ensuring full access to bill texts and summaries.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.